Keytruda improves survival for Asian liver cancer patients

Country

United States

Asian patients with advanced hepatocellular carcinoma were able to live longer after being treated with Keytruda (pembrolizumab), one of the most widely prescribed checkpoint inhibitors for cancer. A Phase 3 trial of 453 patients with the disease achieved an overall survival rate of 21%, potentially acting as a confirmatory study for an accelerated approval given to Keytruda for this indication in the US, the developer Merck & Co Inc announced on 18 January.